Literature DB >> 17158942

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Juyan Zhou1, Yunhua Chen, Setareh Tabibi, Luis Alba, Elizabeth Garber, Lisa Saiman.   

Abstract

Susceptibility (18 antimicrobial agents including high-dose tobramycin) and checkerboard synergy (23 combinations) studies were performed for 2,621 strains of Burkholderia cepacia complex isolated from 1,257 cystic fibrosis patients. Minocycline, meropenem, and ceftazidime were the most active, inhibiting 38%, 26%, and 23% of strains, respectively. Synergy was rarely noted (range, 1% to 15% of strains per antibiotic combination).

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17158942      PMCID： PMC1803131          DOI： 10.1128/AAC.00954-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Burkholderia cepacia infections in cystic fibrosis.

Authors:  J L Burns; L Saiman
Journal:  Pediatr Infect Dis J       Date:  1999-02       Impact factor: 2.129

Review 2.  Cystic fibrosis: pathogenesis, pulmonary infection, and treatment.

Authors:  R B Moss
Journal:  Clin Infect Dis       Date:  1995-10       Impact factor: 9.079

3.  Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates.

Authors:  J D McMenamin; T M Zaccone; T Coenye; P Vandamme; J J LiPuma
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

4.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia.

Authors:  S D Aaron; W Ferris; D A Henry; D P Speert; N E Macdonald
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

5.  The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Jeffrey L Blumer; Lisa Saiman; Michael W Konstan; David Melnick
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

6.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

Review 7.  Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.

Authors:  R E Hancock
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

8.  Pseudomonas cepacia: pulmonary infection in patients with cystic fibrosis.

Authors:  R F Taylor; H Gaya; M E Hodson
Journal:  Respir Med       Date:  1993-04       Impact factor: 3.415

9.  Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).

Authors:  Bindu M Nair; K-John Cheung; Adam Griffith; Jane L Burns
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

10.  Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes.

Authors:  O C Tablan; W J Martone; C F Doershuk; R C Stern; M J Thomassen; J D Klinger; J W White; L A Carson; W R Jarvis
Journal:  Chest       Date:  1987-04       Impact factor: 9.410
View more
  38 in total

Review 1.  Bloodstream infections after solid-organ transplantation.

Authors:  Antonios Kritikos; Oriol Manuel
Journal:  Virulence       Date:  2016-01-14       Impact factor: 5.882

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex.

Authors:  David E Greenberg; Kimberly R Marshall-Batty; Lauren R Brinster; Kol A Zarember; Pamela A Shaw; Brett L Mellbye; Patrick L Iversen; Steven M Holland; Bruce L Geller
Journal:  J Infect Dis       Date:  2010-06-15       Impact factor: 5.226

Review 4.  When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

5.  Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa.

Authors:  Damien Roux; Molly Weatherholt; Bradley Clark; Mihaela Gadjeva; Diane Renaud; David Scott; David Skurnik; Gregory P Priebe; Gerald Pier; Craig Gerard; Deborah R Yoder-Himes
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

Review 6.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

7.  Competitive Growth Enhances Conditional Growth Mutant Sensitivity to Antibiotics and Exposes a Two-Component System as an Emerging Antibacterial Target in Burkholderia cenocepacia.

Authors:  April S Gislason; Matthew Choy; Ruhi A M Bloodworth; Wubin Qu; Maria S Stietz; Xuan Li; Chenggang Zhang; Silvia T Cardona
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

8.  Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.

Authors:  Laurent Poirel; José-Manuel Rodriguez-Martinez; Patrick Plésiat; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 9.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

Review 10.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.